{
    "clinical_study": {
        "@rank": "124199", 
        "arm_group": [
            {
                "arm_group_label": "CAT-1004 Dose #1", 
                "arm_group_type": "Experimental", 
                "description": "Single dose #1"
            }, 
            {
                "arm_group_label": "Salsalate + DHA", 
                "arm_group_type": "Active Comparator", 
                "description": "Single dose #2"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single Dose #3"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to assess mechanistic blood biomarkers of CAT-1004 in healthy\n      humans."
        }, 
        "brief_title": "A Study of CAT-1004 Biomarkers in Healthy Subjects", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Assessment of Mechanistic Blood Biomarkers in Healthy Humans", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Good health as determined by medical history, vital signs, EGC, physical exam and\n             clinical lab results\n\n          -  BMI between 18 and 30 kg/m2 inclusive\n\n        Exclusion Criteria:\n\n          -  Viral or bacterial infection within 21 days prior to randomization\n\n          -  Use of prescription drugs, nonprescription drugs, herbals and dietary supplements\n             within 7 days prior to randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670773", 
            "org_study_id": "CAT-1004-103"
        }, 
        "intervention": [
            {
                "arm_group_label": "CAT-1004 Dose #1", 
                "intervention_name": "CAT-1004", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Salsalate + DHA", 
                "intervention_name": "Salsalate + DHA", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sodium Salicylate", 
                "Salicylsalicylic acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 29, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brighton", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02135"
                }, 
                "name": "ProMedica"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Single Center, Biomarker Study in Healthy Subjects Receiving Single Doses of CAT-1004", 
        "other_outcome": {
            "measure": "Other biomarkers including select cytokines and RNA gene expression may also be assessed", 
            "safety_issue": "No", 
            "time_frame": "Pre/post each of 3 Single doses"
        }, 
        "overall_official": {
            "affiliation": "Catabasis", 
            "last_name": "Joanne Donovan, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activity p65 following ex vivo lipopolysaccharide stimulation", 
            "safety_issue": "No", 
            "time_frame": "Pre/post each of 3 Single doses"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670773"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Catabasis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Catabasis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}